Comparison of risperidone oral solution and intramuscular haloperidol with the latter shifting to oral therapy for the treatment of acute agitation in patients with schizophrenia

International Clinical Psychopharmacology

Volumn 27, Issue 2, 2012, Pages 107-113

  Fang, Maosheng ^a,b   Chen, Honghui ^b   Li, Le Hua ^a   Wu, Renrong ^a   Li, Yi ^b   Liu, Lianzhong ^b   Ye, Meng ^b   Huang, Jizhong ^c   Zhu, Suoyu ^c   Wang, Gang ^d   Zhang, Qinge ^d   Zheng, Hongbo ^e   Zhang, Lulu ^e   Wang, Bo ^f   Zhou, Jianchu ^f   Zhao, Jing Ping ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c SHANGHAI MENTAL HEALTH CENTER   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

^e Guangzhou Brain Hospital   (China)

^f SHANDONG MENTAL HEALTH CENTER   (China)

Author keywords

Efficacy; Haloperidol; Risperidone; Safety; Schizophrenia

Indexed keywords

CLONAZEPAM; HALOPERIDOL; RISPERIDONE;

ADULT; AKATHISIA; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HOSPITAL; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESTLESSNESS; SCHIZOPHRENIA; TACHYCARDIA; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; CHINA; CLONAZEPAM; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HALOPERIDOL; HUMANS; HYPNOTICS AND SEDATIVES; INJECTIONS, INTRAMUSCULAR; MALE; PSYCHOMOTOR AGITATION; RISPERIDONE; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84862823788     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32834fc431     Document Type: Article

References (18)

1. Allen MH (2000). Managing the agitated psychotic patient: a reappraisal of the evidence. J Clin Psychiatry 61 (Suppl 14):11-20. (Pubitemid 32064772)
2. Allen MH, Carpenter D, Sheets JL, Miccio S, Ross R (2003).What do consumers say they want and need during a psychiatric emergency? J Psychiatr Pract 9:39-58. (Pubitemid 36717621)
3. Allen MH, Currier GW, Carpenter D, Ross R, Docherty JP (2005). Expert consensus guidelines on the treatment of behavioral emergencies. J Psychiatr Pract 11 (Suppl 1):1-108.
4. Battaglia J (2005). Pharmacological management of acute agitation. Drug 65:1207-1222. (Pubitemid 41032047)
5. Currier GW, Simpson GM (2001). Risperidone liquid concentrate and oral lorazepam versus IM haloperidol and IM lorazepam for treatment of psychotic agitation. J Clin Psychiatry 62:153-157. (Pubitemid 32270087)
6. Currier GW, Chou JCY, Feifel D, Bossie CA, Turkoz I, Mahmoud RA, et al. (2004). Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloeridol and lorazepam. J Clin Psychiatry 65:386-394.
7. Hassaballa HA, Balk RA (2003). Torsade de pointes associated with the administration of intravenous haloperidol: a review of the literature and practical guidelines for use. Expert Opin Drug Safety 2:543-547.
8. Hughes DH, Kleespies PM (2003). Treating aggression in the psychiatric emergency service. J Clin Psychiatry 64:10-15. (Pubitemid 36418558)
9. Janssen Pharmaceutica (2003). Risperidone (Risperdal) Package Insert. Titusville, NJ, USA: Janseen Pharmaceutica.
10. Kay SR, Fiszbein A, Opler LA (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276. (Pubitemid 18039085)
11. Lejeune J, Larmo I, Chrzanowski W, Witte R, Karavatos A, Schreiner A, et al. (2004). Oral risperidone plus oral lorazepam versus standard care with intramuscular conventional neuroleptics in the initial phase of treating individuals with acute psychosis. Int Clin Psychopharmacol 19: 259-269. (Pubitemid 39141942)
12. Leucht S, Pitschel-Walz G, Abraham D, Kissling W (1999). Efficacy and extrapyramidal side-effects of the new antipsychotics olazapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res 35:51-68. (Pubitemid 29023554)
13. Miller DD (2004). Atypical antipsychotics: sleep, sedation, and efficacy. Prim Care companion. J Clin Psychiatry 6 (Suppl 2):3-7.
14. Perkins DO (2002). Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 63:1121-1128. (Pubitemid 36084056)
15. Thomson PDR (2005). Physician's desk reference. 59th ed. Montvale, NJ: Thomson Healthcare.
16. Woodward ND, Purdon SE, Meltzer HY, Zald DH (2005). A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 8: 457-472. (Pubitemid 41002500)
17. Wright P, Lindborg SR, Birkett M, Meehan K, Jones B, Alaka K, et al. (2003a). Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 h of treatment. Can J Psychiatry 48:716-721. (Pubitemid 38197030)
18. Wright P, Meehan K, Birkett M, Lindborg SR, Taylor CC, Morris P, et al. (2003b). A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy. Clin Ther 25: 1420-1428. (Pubitemid 36677285)